BRIEF published on 12/11/2025 at 23:05, 3 months 7 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 3 months 7 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 4 months ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 4 months ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 4 months 6 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 4 months 6 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 5 months 9 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 5 months 9 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 7 months 6 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 7 months 6 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 03/19/2026 at 14:20, 1 hour 34 minutes ago CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/19/2026 at 13:50, 2 hours 4 minutes ago Predictiv AI Appoints Multi-Agent Systems Pioneer Professor George Rzevski as Strategic Advisor to Advance Swarm AI Platforms
Published on 03/19/2026 at 13:30, 2 hours 24 minutes ago Hillcrest Energy Technologies CEO Don Currie Discusses ZVS Technology and Commercialization Progress in Stocks To Watch Investor Interview
Published on 03/19/2026 at 13:30, 2 hours 24 minutes ago ACCESS Newswire Reports Fourth Quarter and Full Year 2025 Results
Published on 03/19/2026 at 13:15, 2 hours 39 minutes ago Worksport Presents New Premium "Game Changer" Tonneau Cover Model to Industry Buyers at Keystone BIG Show; Initiates Pre-Orders Ahead of Near-Term Commercial Launch
Published on 03/19/2026 at 15:15, 39 minutes ago tick Trading Software AG has published the 2024/2025 Annual Report and invites to the 2026 Annual General Meeting
Published on 03/19/2026 at 15:15, 39 minutes ago MEDICLIN invites you to the 2026 virtual press conference on the financial statements for the year 2025
Published on 03/19/2026 at 15:02, 52 minutes ago Knorr-Bremse proposes higher dividend – € 1.90 per share planned
Published on 03/19/2026 at 15:00, 53 minutes ago SMT Scharf AG continues advancing its Strategy 2026 to expand the sales regions and product portfolio for business growth
Published on 03/19/2026 at 08:45, 7 hours 9 minutes ago Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 8 hours 54 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 8 hours 54 minutes ago 2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 20 hours 12 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
